Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 1
2010 1
2015 4
2016 6
2017 6
2018 10
2019 19
2020 15
2021 21
2022 20
2023 26
2024 30
2025 43
2026 32

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

210 results

Results by year

Filters applied: . Clear all
Page 1
Excess Apolipoprotein B and Cardiovascular Risk in Women and Men.
Johannesen CDL, Langsted A, Nordestgaard BG, Mortensen MB. Johannesen CDL, et al. J Am Coll Cardiol. 2024 Jun 11;83(23):2262-2273. doi: 10.1016/j.jacc.2024.03.423. J Am Coll Cardiol. 2024. PMID: 38839200 Free article.
BACKGROUND: Low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B (apoB) are highly correlated measures of atherogenic lipoproteins. OBJECTIVES: The study investigators hypothesized that excess apoB is associated with an increased risk of myocardia …
BACKGROUND: Low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B (apoB) are highly correlated measures of atheroge …
The LDL cumulative exposure hypothesis: evidence and practical applications.
Ference BA, Braunwald E, Catapano AL. Ference BA, et al. Nat Rev Cardiol. 2024 Oct;21(10):701-716. doi: 10.1038/s41569-024-01039-5. Epub 2024 Jul 5. Nat Rev Cardiol. 2024. PMID: 38969749 Review.
The trapping of LDL and other apolipoprotein B-containing lipoproteins within the artery wall causes atherosclerosis. As more LDL becomes trapped within the artery wall over time, the atherosclerotic plaque burden gradually increases, raising the risk of an a …
The trapping of LDL and other apolipoprotein B-containing lipoproteins within the artery wall causes atherosclerosis. As more …
Saturated fats and cardiovascular health: Current evidence and controversies.
Maki KC, Dicklin MR, Kirkpatrick CF. Maki KC, et al. J Clin Lipidol. 2021 Nov-Dec;15(6):765-772. doi: 10.1016/j.jacl.2021.09.049. Epub 2021 Oct 1. J Clin Lipidol. 2021. PMID: 34649831
A diet high in saturated fatty acids (SFA) is a suspected contributor to atherosclerotic cardiovascular disease (ASCVD) risk, in large part because of an effect to raise the low-density lipoprotein cholesterol (LDL-C) concentration. ...Additionally, although the num …
A diet high in saturated fatty acids (SFA) is a suspected contributor to atherosclerotic cardiovascular disease (ASCVD) risk, …
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC Jr, Sperling L, Virani SS, Yeboah J. Grundy SM, et al. Circulation. 2019 Jun 18;139(25):e1082-e1143. doi: 10.1161/CIR.0000000000000625. Epub 2018 Nov 10. Circulation. 2019. PMID: 30586774 Free PMC article.
A healthy lifestyle reduces atherosclerotic cardiovascular disease (ASCVD) risk at all ages. In younger individuals, healthy lifestyle can reduce development of risk factors and is the foundation of ASCVD risk reduction. ...Very high-risk …
A healthy lifestyle reduces atherosclerotic cardiovascular disease (ASCVD) risk at all ages. In younger individuals, healthy l …
Managing Atherosclerotic Cardiovascular Risk in Young Adults: JACC State-of-the-Art Review.
Stone NJ, Smith SC Jr, Orringer CE, Rigotti NA, Navar AM, Khan SS, Jones DW, Goldberg R, Mora S, Blaha M, Pencina MJ, Grundy SM. Stone NJ, et al. J Am Coll Cardiol. 2022 Mar 1;79(8):819-836. doi: 10.1016/j.jacc.2021.12.016. J Am Coll Cardiol. 2022. PMID: 35210038 Free article. Review.
There is a need to identify high-risk features that predict early-onset atherosclerotic cardiovascular disease (ASCVD). ...The authors update current thinking on lipid risk factors such as triglycerides, non-high-density lipoprotein cholesterol, apolipopro …
There is a need to identify high-risk features that predict early-onset atherosclerotic cardiovascular disease (ASCVD). ...The …
High-density lipoprotein revisited: biological functions and clinical relevance.
von Eckardstein A, Nordestgaard BG, Remaley AT, Catapano AL. von Eckardstein A, et al. Eur Heart J. 2023 Apr 21;44(16):1394-1407. doi: 10.1093/eurheartj/ehac605. Eur Heart J. 2023. PMID: 36337032 Free PMC article. Review.
This review aims to provide an update on the role of HDL in health and disease, also beyond ASCVD. Through evolution from invertebrates, HDLs are the principal lipoproteins, while apolipoprotein B-containing lipoproteins first developed in vertebrates. ...Con …
This review aims to provide an update on the role of HDL in health and disease, also beyond ASCVD. Through evolution from invertebrat …
Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia: The SHASTA-2 Randomized Clinical Trial.
Gaudet D, Pall D, Watts GF, Nicholls SJ, Rosenson RS, Modesto K, San Martin J, Hellawell J, Ballantyne CM. Gaudet D, et al. JAMA Cardiol. 2024 Jul 1;9(7):620-630. doi: 10.1001/jamacardio.2024.0959. JAMA Cardiol. 2024. PMID: 38583092 Free PMC article. Clinical Trial.
IMPORTANCE: Severe hypertriglyceridemia (sHTG) confers increased risk of atherosclerotic cardiovascular disease (ASCVD), nonalcoholic steatohepatitis, and acute pancreatitis. ...Plozasiran was associated with dose-dependent increases in low-density lipoprotein chole …
IMPORTANCE: Severe hypertriglyceridemia (sHTG) confers increased risk of atherosclerotic cardiovascular disease (ASCVD), nonal …
Apolipoprotein B modifies the association between lipoprotein(a) and ASCVD risk.
Lai Y, Zhang S, Guo Y, Xu C, Huang M, Zhan R, Liu M, Xiong Z, Huang Y, Liao X, Ma Y, Zhuang X, Jiang J, Wu X. Lai Y, et al. Am Heart J. 2025 Mar;281:157-167. doi: 10.1016/j.ahj.2024.11.014. Epub 2024 Dec 5. Am Heart J. 2025. PMID: 39643097
BACKGROUND: Elevated lipoprotein(a) (Lp[a]) and apolipoprotein B (apoB) are individually associated with the risk of atherosclerotic cardiovascular disease (ASCVD). ...The measurement of apoB can further refine and contextualize the ASCVD ris …
BACKGROUND: Elevated lipoprotein(a) (Lp[a]) and apolipoprotein B (apoB) are individually associated with the risk of at …
World Heart Federation Cholesterol Roadmap 2022.
Ray KK, Ference BA, Séverin T, Blom D, Nicholls SJ, Shiba MH, Almahmeed W, Alonso R, Daccord M, Ezhov M, Olmo RF, Jankowski P, Lanas F, Mehta R, Puri R, Wong ND, Wood D, Zhao D, Gidding SS, Virani SS, Lloyd-Jones D, Pinto F, Perel P, Santos RD. Ray KK, et al. Glob Heart. 2022 Oct 14;17(1):75. doi: 10.5334/gh.1154. eCollection 2022. Glob Heart. 2022. PMID: 36382159 Free PMC article. Review.
Preventing the accumulation of cholesterol-containing atherogenic lipoproteins in the vessel wall is central to any healthcare strategy to prevent ASCVD. Advances in current concepts about reducing cumulative exposure to apolipoprotein B (apo B) cholesterol-c …
Preventing the accumulation of cholesterol-containing atherogenic lipoproteins in the vessel wall is central to any healthcare strategy to p …
Familial Hypercholesterolemia: Global Burden and Approaches.
Tokgozoglu L, Kayikcioglu M. Tokgozoglu L, et al. Curr Cardiol Rep. 2021 Sep 4;23(10):151. doi: 10.1007/s11886-021-01565-5. Curr Cardiol Rep. 2021. PMID: 34480646 Review.
In most cases, mutations in the LDL-receptor (LDLR) gene and to a lesser degree in the apolipoprotein B-100 (APOB), proprotein convertase subtilisin/kexin type 9 (PCSK9), and the LDL-receptor adaptor protein 1 (LDLRAP1) genes cause FH. ...Early diagnosis and initiat …
In most cases, mutations in the LDL-receptor (LDLR) gene and to a lesser degree in the apolipoprotein B-100 (APOB), proprotein …
210 results